As of September 7, 2026, the valsartan personal injury litigation (MDL No. 2875, D.N.J.) remains active but has hit turbulence. The first scheduled bellwether trial, Roberts v. Zhejiang Huahai Pharmaceutical, was called off in November 2025 after the judge excluded the plaintiff’s medical causation expert. A second wave of bellwether trials has continued through 2026, with Judge Renée Marie Bumb extending expert-discovery deadlines for both sides. Separately, economic-loss class action settlements with Hetero, Aurobindo, and Vivimed (roughly $26.5 million combined) reached a final approval hearing on June 30, 2026 — those cover consumers who purchased contaminated pills, not personal injury or cancer claims, which remain unresolved.
Last updated: September 2026
The valsartan lawsuit is one of the largest pharmaceutical contamination cases in U.S. history, and in 2026, it is still very much active with settlements, trials, and new claim filings all moving forward.
If you or someone you love took a valsartan blood pressure medication and later developed cancer, you may be entitled to financial compensation. The contamination was real. The harm was documented. And the legal system is still processing claims.
This article covers the full picture for 2026: who qualifies, how much you could receive, what has changed in the MDL, and what deadlines you absolutely cannot miss.
One fact that surprises most people: over 1,000 personal injury lawsuits remain consolidated in federal court in New Jersey, and individual trial dates are being scheduled throughout 2026.
Valsartan Lawsuit Update 2026: Where Things Stand Right Now
The valsartan lawsuit in 2026 is in a critical phase, with individual bellwether trials proceeding and settlement negotiations continuing for claimants with documented cancer diagnoses.
The Multi-District Litigation, known as MDL 2875, is being managed in the U.S. District Court for the District of New Jersey under Judge Robert Kugler. As of 2026, thousands of cases remain in the pipeline.
Several manufacturer defendants have reached partial settlements in prior years. However, not all defendants have settled. That means some claimants are still waiting for trial verdicts or individual settlement offers.
The case has moved past the early procedural stages. Expert witnesses have been deposed. Bellwether cases have been selected and scheduled. The courts are now actively pushing toward resolution.
| Milestone | Status in 2026 |
|---|---|
| MDL Court | U.S. District Court, District of New Jersey |
| MDL Number | MDL No. 2875 |
| Presiding Judge | Judge Robert Kugler |
| Total Cases Filed | Thousands, with active trials ongoing |
| Settlement Phase | Partial settlements reached; trials ongoing |
| Bellwether Trials | Scheduled throughout 2026 |
This is not a case that has quietly disappeared. It is moving. And if you have not yet filed, time is working against you.
Valsartan Lawsuit Payout: How Much Are People Getting?
Valsartan lawsuit payouts vary widely depending on the cancer diagnosis, the duration of contaminated drug use, and the defendant named in the claim.
Think of it like a personal injury claim for a car accident. The worse the injury, the higher the payout. Someone with a serious cancer diagnosis that required surgery and chemotherapy will receive far more than someone with early-stage cancer caught early.
Publicly available settlement information and legal reporting indicate that personal injury claimants with serious cancer diagnoses have received settlements ranging from tens of thousands to several hundred thousand dollars. Some high-severity cases have exceeded $1 million in reported verdicts.
For economic damages, medical expenses, lost income, and pain and suffering are all factored in. Non-economic damages like emotional distress also count.
| Injury Tier | Estimated Payout Range |
|---|---|
| Tier 1: Minor Diagnosis, Early Stage | $25,000 to $75,000 |
| Tier 2: Moderate Cancer, Treated Successfully | $75,000 to $250,000 |
| Tier 3: Severe Cancer, Ongoing Treatment | $250,000 to $500,000+ |
| Tier 4: Terminal Diagnosis or Wrongful Death | $500,000 to $1,000,000+ |
These are general ranges based on reported mass tort payout patterns and legal reporting. Your actual offer depends on specific facts of your case.
Key Takeaway: Payouts in the valsartan lawsuit depend on cancer severity, and serious cases have resulted in settlements well above $100,000.
Who Qualifies for the Valsartan Lawsuit?
You qualify for the valsartan lawsuit if you took a recalled valsartan medication and were diagnosed with a linked cancer after taking it.
The basic eligibility formula is straightforward: contaminated drug plus cancer diagnosis equals potential claim. But the details matter.
You need to show that you actually took one of the recalled valsartan products. Pharmacy records, prescription history, and insurance claims all serve as proof. This is documentation your pharmacist or doctor can help you pull together.
You also need a qualifying cancer diagnosis. Not every cancer qualifies. The lawsuit focuses on cancers that scientific and medical evidence links to NDMA and NDEA exposure.
General Eligibility Checklist:
- You took a valsartan medication made by ZHP, Teva, Torrent, Mylan, or Aurobindo
- Your medication was part of the FDA recall issued starting in July 2018
- You were diagnosed with a qualifying cancer during or after taking the medication
- Your cancer diagnosis falls within the statute of limitations in your state
If you took brand-name Diovan made by Novartis, that product was not part of the contamination recall. The contamination affected generic valsartan manufacturers, not the original brand.
Valsartan Lawsuit Eligibility Requirements: The Fine Print
The eligibility requirements for the valsartan lawsuit go beyond just taking the medication and getting sick.
Courts and attorneys look at what lawyers call “proximate causation.” That means your cancer must be plausibly connected to NDMA exposure from valsartan, not from another independent cause.
Specific Eligibility Requirements:
- Drug confirmation: Pharmacy records must show you were dispensed recalled valsartan
- Duration of use: Most claims involve use of at least several months to over a year
- Diagnosis timing: Cancer must have developed after or during the period of contaminated drug use
- Cancer type: Must be one of the types scientifically linked to nitrosamine exposure
- Statute of limitations: Varies by state, typically 2 to 3 years from discovery of harm
One thing many people miss: the statute of limitations clock often starts from when you learned your valsartan was recalled or when your cancer was diagnosed, not from when you started taking the drug.
| Requirement | Details |
|---|---|
| Drug Manufacturer | ZHP, Teva, Torrent, Mylan, or Aurobindo |
| Prescription Period | During recall window (2012 to 2018 primary exposure period) |
| Minimum Use | Typically several months of consistent use |
| Diagnosis Required | Yes, documented cancer diagnosis required |
| Medical Records | Required to substantiate claim |
Valsartan Lawsuit Cancer Types Covered: Which Diagnoses Qualify?
The valsartan lawsuit covers cancers that scientific research has linked to NDMA and NDEA contamination, and not every cancer type qualifies.
NDMA is classified as a probable human carcinogen by the World Health Organization. Animal studies have shown it causes liver, lung, and kidney cancers. Human epidemiological data adds stomach, colorectal, and esophageal cancers to the list.
Cancer Types Recognized in the Valsartan Litigation:
- Liver cancer (hepatocellular carcinoma)
- Stomach cancer (gastric cancer)
- Colorectal cancer
- Esophageal cancer
- Bladder cancer
- Kidney cancer
- Lung cancer (in some cases, depending on expert testimony)
- Small intestine cancer
- Leukemia (certain blood cancers linked to nitrosamine exposure)
Pancreatic cancer has been discussed in some claims but faces more scientific scrutiny for causation. Non-melanoma skin cancers are generally not included.
The strength of your claim depends partly on how directly science supports the link between NDMA exposure and your specific cancer type. Liver and stomach cancers have the strongest body of evidence.
Key Takeaway: Liver, stomach, colorectal, and esophageal cancers are among the strongest qualifying diagnoses in the valsartan lawsuit, backed by the most consistent scientific evidence.
Valsartan Settlement Amount: What the Numbers Look Like in 2026
The valsartan settlement amount in 2026 depends on which defendant your claim is against and whether that defendant has reached a global settlement agreement.
Some defendants settled large groups of cases in 2023 and 2024. Others, particularly ZHP, have had more complicated financial situations. That financial complexity directly affects how much money is actually available to pay claimants.
Unlike a car accident where one insurance company writes a check, the valsartan litigation involves multiple manufacturer defendants, each with separate legal teams and separate settlement funds.
Retailer defendants like pharmacies and distributors have also been named. Some of these parties reached earlier settlements. The personal injury claims against manufacturers carry the largest potential payouts.
| Defendant Type | Settlement Status (2026) | Payout Impact |
|---|---|---|
| ZHP (Primary Manufacturer) | Ongoing litigation and partial resolution | High stakes, contested amounts |
| Teva Pharmaceuticals | Settlement negotiations active | Moderate to high payout potential |
| Torrent Pharmaceuticals | Settlement discussions ongoing | Moderate payout potential |
| Distributors/Retailers | Some early settlements reached | Lower individual payouts |
| Novartis (Diovan brand) | Not named in contamination claims | Not applicable |
Attorney fees typically run 33% to 40% of gross settlements in contingency-based mass tort cases. This is standard for pharmaceutical litigation.
How Much Will I Get From the Valsartan Lawsuit?
Your individual valsartan lawsuit payout depends on your specific medical history, the defendant responsible for your medication, and the strength of your documented evidence.
There is no single universal number. Think of it the way you would think about a personal injury claim after a serious accident. Two people hit by the same car can walk away with very different settlements based on their injuries, their medical bills, and how well their attorneys argue the case.
What drives your number up:
- A serious or terminal cancer diagnosis
- Long-term use of the contaminated drug
- High medical bills and documented lost income
- Clear pharmacy records confirming recalled valsartan use
- Strong expert medical testimony linking your cancer to NDMA
What drives your number down:
- Short duration of contaminated drug use
- Other significant cancer risk factors like smoking or family history
- Missing or incomplete pharmacy records
- Cancer types with weaker scientific causation links
The simplest way to get a real estimate is to speak with a mass tort attorney who handles pharmaceutical cases. Most offer free case evaluations and work on contingency, meaning you pay nothing unless you win.
Valsartan MDL Update 2026: What Is Happening in Court
The valsartan MDL in 2026 is entering what legal professionals call the “trial and resolution” phase, where individual cases move toward either settlement or jury verdict.
MDL stands for Multi-District Litigation. It is not a class action. Each plaintiff in MDL 2875 has their own individual lawsuit. The MDL structure just groups them together for pretrial proceedings to save court time.
The practical difference matters. In a class action, every member gets the same payout. In an MDL, each claimant can negotiate their own settlement amount or go to trial individually.
Bellwether trials are test cases selected to gauge how juries respond to the evidence. Their outcomes in 2026 will directly influence whether defendants push to settle remaining cases quickly or fight each one in court.
| MDL Phase | Description | Status in 2026 |
|---|---|---|
| Case consolidation | All related cases grouped | Completed |
| Discovery | Evidence gathering and depositions | Substantially complete |
| Expert witness phase | Scientific and medical experts deposed | Ongoing/Complete for key experts |
| Bellwether selection | Test cases chosen | Completed |
| Bellwether trials | Test verdicts guiding settlement | Active in 2026 |
| Mass settlement negotiations | Bulk deals for remaining claimants | Active in 2026 |
Key Takeaway: The valsartan MDL in 2026 is at its most decisive point, with bellwether trials setting the tone for how hundreds of remaining cases will resolve.
Valsartan Class Action Settlement: Is This a Class Action or Not?
The valsartan lawsuit is not a traditional class action settlement. It is a mass tort MDL, which is an important distinction that affects how you get paid.
In a class action, a settlement fund is divided among all members, often resulting in small individual payouts of a few dollars to a few hundred dollars. The valsartan litigation is different.
Because it is an MDL, each claimant’s case is treated individually. Your payout reflects your personal damages. Someone with a severe cancer diagnosis receives far more than someone with a less serious injury.
There is one class action component within the broader valsartan litigation. Consumers who took recalled valsartan but did not develop cancer have pursued medical monitoring claims. These claims seek coverage for ongoing cancer screenings.
The medical monitoring class action asks the court to require defendants to pay for regular screenings for exposed patients who have not yet developed cancer but face elevated risk.
| Litigation Type | Who It Covers | Expected Payout |
|---|---|---|
| Personal Injury MDL | Cancer diagnosed patients | Tens of thousands to millions |
| Medical Monitoring Class Action | Exposed patients without cancer | Medical screening coverage |
| Wrongful Death Claims | Family of deceased patients | High-value individual claims |
If you took contaminated valsartan but have no cancer diagnosis, you may still have rights under the medical monitoring claims.
Valsartan Recall Lawsuit: How the Recall Started Everything
The valsartan recall lawsuit traces directly back to July 2018, when the FDA announced that valsartan products made by ZHP contained dangerously high levels of NDMA.
NDMA is a chemical byproduct that formed during the manufacturing process at ZHP’s facility in China. The company had changed its manufacturing process in 2012, and that change introduced the contamination. It took six years for anyone to catch it.
When the FDA tested the products, they found NDMA levels that far exceeded acceptable limits. The agency considers any NDMA exposure above 0.096 micrograms per day to be a risk. Some valsartan tablets contained hundreds of times that amount.
The recall cascaded quickly. Teva, Torrent, Mylan, and other generic manufacturers who sourced their valsartan API (active pharmaceutical ingredient) from ZHP all issued their own recalls.
By the end of 2018, millions of valsartan tablets had been pulled from shelves. Patients who had been taking these medications daily for years, believing they were safe, learned they had been unknowingly exposed to a carcinogen every single day.
That background is what fuels the lawsuit. These were not isolated incidents. This was systemic contamination affecting millions of patients.
Valsartan NDMA Contamination Lawsuit: What the Chemical Actually Did
The valsartan NDMA contamination lawsuit is built on the argument that manufacturers knowingly or negligently allowed a carcinogen to enter the drug supply.
NDMA stands for N-Nitrosodimethylamine. It is an industrial chemical once used in rocket fuel and to make liquid explosives. It is also found in small amounts in certain foods and water. But the doses found in contaminated valsartan were not small.
When you take a tablet contaminated with high NDMA levels every day for years, the cumulative exposure creates significant cancer risk. Studies published in leading medical journals have found statistically elevated rates of liver, gastric, and colorectal cancers in long-term valsartan users.
A second contaminant, NDEA (N-Nitrosodiethylamine), was found in some valsartan products as well. NDEA is also classified as a probable human carcinogen and carries similar cancer risks.
The legal argument is clear: manufacturers had a duty to ensure their products were safe. They failed. Patients were harmed. The lawsuit seeks to hold them financially accountable for that failure.
| Contaminant | Full Name | Cancer Risk Classification |
|---|---|---|
| NDMA | N-Nitrosodimethylamine | Probable human carcinogen (WHO Group 2A) |
| NDEA | N-Nitrosodiethylamine | Probable human carcinogen (WHO Group 2A) |
Key Takeaway: The NDMA and NDEA contamination found in recalled valsartan was not trace-level exposure. For many patients, daily ingestion continued for years, creating documented cancer risks.
Valsartan Lawsuit Filing Deadline 2026: Do Not Miss This
The valsartan lawsuit filing deadline in 2026 is not a single national date. It varies by state, and missing it means losing your right to sue entirely.
This is the statute of limitations. For pharmaceutical injury cases, most states allow 2 to 3 years from the date you discovered your harm. “Discovery” typically means either the date your valsartan was recalled or the date your cancer was diagnosed, whichever came later.
If your valsartan was recalled in 2018 and you were diagnosed with cancer in 2020, your clock likely started in 2020. A 3-year statute of limitations would put your deadline around 2023. If you have not filed yet, this is urgent.
However, some states toll (pause) the statute of limitations for pharmaceutical cases, or have discovery rules that push the start date forward. This is why speaking with an attorney quickly is so important.
| State Statute of Limitations | Time From Discovery |
|---|---|
| Most states | 2 to 3 years |
| California | 3 years for product liability |
| New York | 3 years |
| Florida | 2 years (after recent reform) |
| Texas | 2 years |
| Pennsylvania | 2 years |
Do not assume you have missed your window without speaking to an attorney. Tolling rules, discovery rules, and state-specific exceptions can extend deadlines in ways that are not obvious to non-lawyers.
ZHP Valsartan Lawsuit: The Company at the Center of the Case
ZHP, formally known as Zhejiang Huahai Pharmaceutical, is the Chinese drug manufacturer at the center of the valsartan contamination crisis.
ZHP was the original source of contaminated valsartan API shipped to generic drug makers across the U.S. and Europe. Their manufacturing process change in 2012 is what introduced NDMA into the drug supply.
The company has faced both U.S. civil litigation and regulatory consequences. The FDA placed ZHP on import alert, effectively banning their products from entering the U.S. The company’s financial condition has been a recurring issue in settlement negotiations.
Because ZHP is a Chinese company, enforcing U.S. court judgments against them is more complex than pursuing a domestic manufacturer. This is one reason claimants whose medications were distributed by U.S.-based companies like Teva and Torrent often have a more direct path to recovery.
ZHP has been a defendant in MDL 2875, and settlement discussions involving ZHP have been ongoing. The financial complexities have led to extended negotiations compared to some other defendants.
| ZHP Key Facts | Details |
|---|---|
| Full Name | Zhejiang Huahai Pharmaceutical Co., Ltd. |
| Country of Operation | China |
| Role in Case | Primary source of contaminated valsartan API |
| Contamination Introduced | 2012 (manufacturing process change) |
| FDA Action | Import alert; products banned from U.S. |
| MDL Role | Named defendant in MDL 2875 |
Valsartan Blood Pressure Medication Lawsuit: Why This Drug Was So Widely Used
Valsartan is a commonly prescribed blood pressure medication taken by millions of Americans, which is exactly why the contamination affected so many people.
It belongs to a class of drugs called angiotensin receptor blockers, or ARBs. Doctors prescribe it to treat high blood pressure, heart failure, and to protect kidney function in patients with diabetes.
Many patients take valsartan for years, sometimes for the rest of their lives. That long-term daily use is what made the contamination so dangerous. A patient taking valsartan from 2012 through 2018 received contaminated pills every single day for up to six years.
Brand-name valsartan, sold as Diovan by Novartis, was not contaminated. The issue was specific to generic manufacturers sourcing their API from ZHP. Generic drugs account for roughly 90% of all prescriptions filled in the U.S., so the market penetration of contaminated valsartan was enormous.
Many patients had no idea they were taking the generic version. Your prescription label might just say “valsartan.” Checking whether it was manufactured using ZHP’s API requires looking at pharmacy records and lot numbers associated with the recall.
Valsartan Personal Injury Claim: How to File in 2026
Filing a valsartan personal injury claim in 2026 starts with gathering your medical records and prescription history.
The process is more straightforward than most people expect. You do not file directly with the court. You hire a mass tort attorney, typically on a contingency basis (no upfront cost), and they file the lawsuit on your behalf.
Steps to File a Valsartan Personal Injury Claim:
- Collect all pharmacy records showing valsartan prescriptions
- Gather your cancer diagnosis records, including pathology reports
- Request your full medical history related to cancer treatment
- Contact a mass tort attorney for a free case evaluation
- Sign a contingency agreement (you pay only if you win)
- Your attorney files your claim in MDL 2875 or appropriate state court
- Your case proceeds through discovery, negotiation, or trial
Most attorneys handling valsartan cases work on a contingency fee of 33% to 40%. You pay nothing upfront. If you lose, you owe nothing. If you win or settle, the attorney takes their percentage from the recovery.
The key is not waiting. Every day you delay is a day closer to a potential deadline that could permanently bar your claim.
Key Takeaway: Filing a valsartan personal injury claim in 2026 is accessible to anyone with pharmacy records and a qualifying cancer diagnosis, with most attorneys charging zero upfront fees.
Valsartan Lawsuit Status: Where Each Part of the Case Stands Today
The valsartan lawsuit status in 2026 shows a case that is active, advancing, and approaching final resolution for many claimants.
The MDL has cleared its major pretrial hurdles. Expert witness battles are largely settled. The science supporting causation has survived multiple Daubert challenges from defense attorneys. That matters because it means plaintiffs can bring their expert testimony to trial.
Several manufacturers have reached settlements covering categories of claimants. New settlements are being negotiated throughout 2026. Claimants who have not yet received settlement offers may be in line as negotiations expand.
For cases that do not settle, trial is the path forward. Individual trials within the MDL framework take longer and involve more uncertainty, but they also offer the possibility of higher verdicts.
| Case Category | Status in 2026 |
|---|---|
| MDL pretrial proceedings | Substantially complete |
| Expert witness admissibility | Plaintiffs’ experts cleared to testify |
| Bellwether trials | Active |
| Manufacturer settlements | Partial; ongoing negotiations |
| Medical monitoring class action | Separate track, still developing |
| New claim filings | Still being accepted for qualifying claimants |
If you are wondering whether it is too late to get involved, the answer for most people with qualifying diagnoses is still no, it is not too late. But the window is narrowing.
Frequently Asked Questions
What is the current status of the valsartan lawsuit in 2026?
The valsartan lawsuit is active in 2026 with bellwether trials underway in MDL 2875 in New Jersey.
Several manufacturers have reached partial settlements, while others continue to negotiate or prepare for trial.
New claims from qualifying claimants are still being accepted, though filing deadlines vary by state.
How much money can I get from the valsartan lawsuit payout?
Payouts vary significantly based on cancer type, severity, and which manufacturer made your medication.
Reported settlements range from tens of thousands of dollars for less severe cases to over one million dollars for terminal diagnoses or wrongful death claims.
Your specific amount will depend on your medical history, documented damages, and the strength of your evidence.
Who qualifies for the valsartan lawsuit in 2026?
You may qualify if you took recalled valsartan made by ZHP, Teva, Torrent, Mylan, or Aurobindo and were later diagnosed with a qualifying cancer.
Pharmacy records proving you received recalled medication and medical documentation of your cancer diagnosis are both required.
Patients who took brand-name Diovan by Novartis do not qualify, as that product was not part of the contamination recall.
What is the filing deadline for the valsartan lawsuit in 2026?
There is no single national deadline. Each state has its own statute of limitations, typically 2 to 3 years from when you discovered the harm.
For many patients diagnosed with cancer after the 2018 recall, the clock has been running since their diagnosis date.
Speaking with a mass tort attorney immediately is the only reliable way to know whether your deadline has passed or how much time you have left.
What cancers are covered in the valsartan lawsuit?
The most recognized qualifying cancers include liver, stomach, colorectal, esophageal, bladder, and kidney cancers.
These are the cancer types with the strongest scientific evidence linking them to NDMA and NDEA exposure.
Blood cancers like certain leukemias have also been included in some claims, while cancers with weaker causation links face more scrutiny from defense experts.
What You Should Do Right Now
The valsartan lawsuit is not waiting for anyone. Cases are moving through the courts. Settlement funds are being distributed. And statutes of limitations are continuing to tick.
If you took valsartan and have been diagnosed with cancer, your path forward starts with two things: pulling your pharmacy records and speaking with an attorney. Both are simpler than most people think.
You do not need money to get started. Mass tort attorneys take these cases on contingency. That means your financial situation is not a barrier to pursuing compensation that may be owed to you.
